In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Having survived the cancer which took his father, Graham Heron, from Bovington, is urging more men to act quickly to avoid falling victim to the most common cancer affecting men in the UK.

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

John Tesh has outlived his prognosis by nearly eight years after doctors told him in 2015 he had only 18 months to live, Page Six reports. The former “Entertainment Tonight” co-host told reporters in ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

An analysis of data from the NCI Cohort Consortium Physical Activity and Cancer work group explored the benefits of recommended activity levels for cancer survivors.

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...